Previous 10 | Next 10 |
Invitae (NVTA) has priced its public offering of ~7.8M common shares at $51.50/share, for expected gross proceeds of ~$400M.Underwriters' over-allotment is an additional ~1.2M shares. Net proceeds will be used for working capital and other general corporate purposes, to acquire or invest in c...
Invitae (NVTA) drops 4.3% in post market hours, after it has commenced an underwritten public offering of $400M of shares of its common stock.Underwriters have an option to purchase up to an additional $60M of shares.Number of shares and price are yet to be determined. For further...
Invitae ([[NVTA]] +4.9%) has launched a new project with Bristol Myers Squibb ([[BMY]] +2.3%), Janssen ([[JNJ]] +1.9%), Novartis and Genentech, a member of the Roche Group, to develop a standardized panel for Minimal residual disease ((MRD)) detection in patients with acute myeloid ...
Genetic testing expert Invitae (NYSE: NVTA) has received the backing of some of the largest pharmaceutical companies in the industry. Bristol Myers Squibb (NYSE: BMY) , Johnson & Johnson (NYSE: JNJ) , Novartis (NYSE: NVS) , and Roche (OTC: RHHBY) ...
Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML) -- Project aims to standardize MRD data generation, assessment and accelerate AML clinical trial programs bri...
Shares of Invitae (NYSE: NVTA) were up 8.9% as of 3:42 p.m. EST on Wednesday. The gain came after Pacific Biosciences of California (NASDAQ: PACB) announced a collaboration with Invitae to expand its whole genome testing capabilities using PacBio's new HiFi sequencing system...
Pacific Biosciences of California (PACB) gains 5% in premarket after announcing a multi-year collaboration with Invitae (NVTA), to begin development of a production-scale high-throughput sequencing platform leveraging PacBio’s HiFi sequencing to expand Invitae’s w...
MENLO PARK, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a multi-year collaboration with Invitae Corporation (NYSE: NVTA), a leading medical genetics comp...
Gainers: GeoVax Labs (GOVX) +83%, Zomedica (ZOM) +82%, TransEnterix (TRXC) +49%, Mesoblast (MESO) +40%, Aileron Therapeutics (ALRN) +29%.Losers: Editas Medicine (EDIT) -16%, Medigus (MDGS) -15%, Jaguar Health (JAGX) -11%, Invita...
For FY20, Invitae (NVTA) reported strong growth in preliminary volume and revenue, signaling continued momentum into 2021.The company generated revenue of $278M+ (~28% Y/Y increase) with billable volume surging ~40% increase to 655K+.Year-end cash and equivalents, restricted cash and marketab...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...